This company listing is no longer active
ZEAL Stock Overview
A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Zealand Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 17.59 |
| 52 Week High | DKK 32.94 |
| 52 Week Low | DKK 9.93 |
| Beta | 1.34 |
| 1 Month Change | 4.02% |
| 3 Month Change | 36.46% |
| 1 Year Change | -38.92% |
| 3 Year Change | -29.50% |
| 5 Year Change | -5.94% |
| Change since IPO | -1.29% |
Recent News & Updates
Zealand Pharma announces private placement of 4.5M new shares
Oct 04Novo Nordisk to pay DKK25M upfront to Zealand Pharma in license deal for Zegalogue
Sep 07Zealand Pharma appoints CFO
Aug 24Zealand Pharma to delist U.S.-listed shares, consolidate trading to Nasdaq Copenhagen
Aug 08Shareholder Returns
| ZEAL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.8% | -0.4% | 1.7% |
| 1Y | -38.9% | -12.5% | 11.5% |
Return vs Industry: ZEAL underperformed the US Biotechs industry which returned -25.6% over the past year.
Return vs Market: ZEAL underperformed the US Market which returned -23.2% over the past year.
Price Volatility
| ZEAL volatility | |
|---|---|
| ZEAL Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: ZEAL's share price has been volatile over the past 3 months.
Volatility Over Time: ZEAL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 237 | Adam Steensberg | www.zealandpharma.com |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management.
Zealand Pharma A/S Fundamentals Summary
| ZEAL fundamental statistics | |
|---|---|
| Market cap | US$1.06b |
| Earnings (TTM) | -US$143.88m |
| Revenue (TTM) | US$38.71m |
Is ZEAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZEAL income statement (TTM) | |
|---|---|
| Revenue | DKK 293.77m |
| Cost of Revenue | DKK 112.39m |
| Gross Profit | DKK 181.38m |
| Other Expenses | DKK 1.27b |
| Earnings | -DKK 1.09b |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 10, 2022
| Earnings per share (EPS) | -23.60 |
| Gross Margin | 61.74% |
| Net Profit Margin | -371.73% |
| Debt/Equity Ratio | 70.9% |
How did ZEAL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/10/01 03:28 |
| End of Day Share Price | 2022/09/29 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zealand Pharma A/S is covered by 25 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura Hindley | Berenberg |
| Kerry Holford | Berenberg |
| Charlie Haywood | BofA Global Research |